Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly and Company discovers, develops ... as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular ...

Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations ... same website for approximately 30 days. The company currently plans to share its full Q4 2024 ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations." "2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines ... immunology to neuroscience. Eli Lilly and Company (NYSE: LLY) will announce ...

2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance Q4 2024 revenue is expected to be ...